A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
Status:
Recruiting
Trial end date:
2025-03-15
Target enrollment:
Participant gender:
Summary
Evaluation of myeloma disease burden is currently suboptimal. This limits treatment planning
and evaluation of residual disease following treatment. 89Zr-DFO-daratumumab is a novel
immunoPET tracer, designed to detect CD38 on myeloma cells and allow visualization of myeloma
in a PET scanner. A phase I study of 89Zr-DFO-daratumumab demonstrated safety and successful
visualization of myeloma with 89Zr-DFO-daratumumab. This will be a phase II study of
89Zr-DFO-daratumumab to evaluate potential clinical applications of this novel imaging agent.